Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic regulatory T cells TRX103

A preparation of off-the-shelf (OTS), allogeneic CD4+ cells engineered to mimic regulatory type 1 (Tr1) cells, with potential immunomodulating activity. Upon infusion of allogeneic regulatory T cells TRX103, these cells secrete the immunomodulatory cytokine interleukin-10 (IL-10) and other cytokines upon exposure to donor T cells, and may additionally stimulate the production of de novo Tr1 cells. This suppresses immune responses and resets the immune system. This may ultimately prevent or reduce graft versus host disease (GvHD). IL-10 plays a key role in controlling inflammation, downregulating immune responses, and inducing immunological tolerance. IL-10 induces both a long-lasting antigen specific T-cell anergy and the differentiation of Tr1 cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic engineered Tr1 regulatory T cells TRX103
allogeneic regulatory type 1 cells TRX103
allogeneic TR1 Tregs TRX103
allogeneic Tregs TRX103
allogeneic type 1 Tregs TRX103
donor-derived regulatory T cells TRX103
Code name:TRX 103
TRX-103
TRX103
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search